Ben Finlay1, Timothy Price2, Peter Hewett1. 1. Department of Surgery, The Queen Elizabeth Hospital, 28 Woodville Road, Woodville South SA 5011, Australia. 2. Department of Haematology and Oncology and University of Adelaide, The Queen Elizabeth Hospital, Woodville South, Australia.
Abstract
BACKGROUND: Neutropenia and thrombocytopenia are well-recognised complications of systemic chemotherapy. In cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC), the interplay between surgical factors and systemic toxicity of chemotherapeutics must be considered when considering post-operative haematological outcomes. We sought to quantify the incidence of these events in cytoreductive surgery and HIPEC at our institution. METHODS: We conducted a single centre, a retrospective cohort study of 50 consecutive patients who underwent cytoreductive surgery and HIPEC from 2002 to 2015. Routine haematological data were analysed and complications classified according to CTCAE 4.0. Subgroup analysis was undertaken to compare those who received or not perioperative systemic chemotherapy. RESULTS: The rate of all-grade post-procedure neutropenia was 4 % (n=2/50); one grade 1, and one grade 4 neutropenia. The patient with grade 4 neutropenia died day 57 post-operatively, despite subsequent growth factor support. Eight percent (n=4/50) of patients had thrombocytopenia preoperatively. The overall rate of post-procedure thrombocytopenia was 46 % with grade 3-4 thrombocytopenia of 4 %. If not present preoperatively, thrombocytopenia onset was on day 1 or 2 post-operatively, with a median duration of 3 days. CONCLUSIONS: Intraperitoneal delivery of chemotherapy as HIPEC can cause haematological toxicity with potentially fatal outcomes. However, the incidence of neutropenia and thrombocytopenia after CRS and HIPEC is low.
BACKGROUND: Neutropenia and thrombocytopenia are well-recognised complications of systemic chemotherapy. In cytoreductive surgery and heated intraperitoneal chemotherapy (HIPEC), the interplay between surgical factors and systemic toxicity of chemotherapeutics must be considered when considering post-operative haematological outcomes. We sought to quantify the incidence of these events in cytoreductive surgery and HIPEC at our institution. METHODS: We conducted a single centre, a retrospective cohort study of 50 consecutive patients who underwent cytoreductive surgery and HIPEC from 2002 to 2015. Routine haematological data were analysed and complications classified according to CTCAE 4.0. Subgroup analysis was undertaken to compare those who received or not perioperative systemic chemotherapy. RESULTS: The rate of all-grade post-procedure neutropenia was 4 % (n=2/50); one grade 1, and one grade 4 neutropenia. The patient with grade 4 neutropenia died day 57 post-operatively, despite subsequent growth factor support. Eight percent (n=4/50) of patients had thrombocytopenia preoperatively. The overall rate of post-procedure thrombocytopenia was 46 % with grade 3-4 thrombocytopenia of 4 %. If not present preoperatively, thrombocytopenia onset was on day 1 or 2 post-operatively, with a median duration of 3 days. CONCLUSIONS: Intraperitoneal delivery of chemotherapy as HIPEC can cause haematological toxicity with potentially fatal outcomes. However, the incidence of neutropenia and thrombocytopenia after CRS and HIPEC is low.
Authors: Reema Hadi; Vanessa Saunders; Olga Utkina; Philip Clingan; Peter Kam; Matthew Links; David L Morris Journal: ANZ J Surg Date: 2006-03 Impact factor: 1.872
Authors: Daphne Hompes; André D'Hoore; Eric Van Cutsem; Steffen Fieuws; Wim Ceelen; Marc Peeters; Kurt Van der Speeten; Claude Bertrand; Hugues Legendre; Joseph Kerger Journal: Ann Surg Oncol Date: 2012-03-07 Impact factor: 5.344
Authors: Carlos Pérez-Ruixo; Belén Valenzuela; José Esteban Peris; Pedro Bretcha-Boix; Vanesa Escudero-Ortiz; José Farré-Alegre; Juan José Pérez-Ruixo Journal: Clin Pharmacokinet Date: 2013-12 Impact factor: 6.447
Authors: Belén Valenzuela; Ricardo Nalda-Molina; Pere Bretcha-Boix; Vanesa Escudero-Ortíz; Maria José Duart; Vicente Carbonell; Manuel Sureda; José Pascual Rebollo; Josep Farré; Antonio Brugarolas; Juan José Pérez-Ruixo Journal: AAPS J Date: 2011-01-06 Impact factor: 4.009
Authors: Laura A Lambert; Terri S Armstrong; J Jack Lee; Suyu Liu; Matthew H G Katz; Cathy Eng; Robert A Wolff; Melissa L Tortorice; Pier Tansey; Santiago Gonzalez-Moreno; Donald H Lambert; Paul F Mansfield Journal: Ann Surg Oncol Date: 2009-05-28 Impact factor: 5.344